Literature DB >> 23723040

Comprehensive analysis of RET gene should be performed in patients with multiple endocrine neoplasia type 2 (MEN 2) syndrome and no apparent genotype-phenotype correlation: an appraisal of p.Y791F and p.C634Y RET mutations in five unrelated Brazilian families.

F O F Valente1, M R Dias da Silva, C P Camacho, I S Kunii, A U Bastos, C C N da Fonseca, H P C Simião, R Tamanaha, R M B Maciel, J M Cerutti.   

Abstract

BACKGROUND: We previously identified a four-generation family with medullary thyroid cancer (MTC) and a germline p.Y791F RET mutation whose cancer lacked a strong genotype-phenotype correlation. The entire gene coding region of the RET gene should be sequenced when genotype-phenotype discrepancies are observed in patients with multiple endocrine neoplasia type 2 (MEN 2), even if a RET hotspot mutation has been identified.
METHODS: A new genetic test was performed in the index case of this family with the p.Y791F RET germline mutation. The entire coding region of the RET gene was investigated by direct sequencing of PCR products. Once a mutation was identified, the target exon was sequenced in all at-risk relatives.
RESULTS: An additional p.C634Y germline mutation in the RET gene was identified in the reported family. The double mutation occurred in cis and segregated with the phenotype. Through the Brazilian Genetic Screening Program developed at our institution, we additionally report the combination of these two mutations (p.C634Y/p.Y791F) in the RET gene in four other unrelated families. The overall penetrance of MTC and pheochromocytoma in patients with the p.C634Y/p.Y791F mutations was 79% and 13%, respectively.
CONCLUSION: Our data emphasises that a comprehensive analysis of the RET gene may reveal multiple germline mutations in MEN 2 patients who exhibit an atypical clinical course of the disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23723040     DOI: 10.3275/8997

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  27 in total

1.  Y791F RET mutation and early onset of medullary thyroid carcinoma in a Brazilian kindred: evaluation of phenotype-modifying effect of germline variants.

Authors:  Rosana Tamanaha; Cléber P Camacho; Elza S Ikejiri; Rui M B Maciel; Janete M Cerutti
Journal:  Clin Endocrinol (Oxf)       Date:  2007-07-04       Impact factor: 3.478

2.  Various penetrance of familial medullary thyroid carcinoma in patients with RET protooncogene codon 790/791 germline mutations.

Authors:  Guido Fitze; Mandy Schierz; Jan Bredow; Hans D Saeger; Dietmar Roesner; Hans K Schackert
Journal:  Ann Surg       Date:  2002-11       Impact factor: 12.969

Review 3.  Guidelines for diagnosis and therapy of MEN type 1 and type 2.

Authors:  M L Brandi; R F Gagel; A Angeli; J P Bilezikian; P Beck-Peccoz; C Bordi; B Conte-Devolx; A Falchetti; R G Gheri; A Libroia; C J Lips; G Lombardi; M Mannelli; F Pacini; B A Ponder; F Raue; B Skogseid; G Tamburrano; R V Thakker; N W Thompson; P Tomassetti; F Tonelli; S A Wells; S J Marx
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

4.  Double germline mutations in the RET Proto-oncogene in MEN 2A and MEN 2B kindreds.

Authors:  S Dvorakova; E Vaclavikova; A Ryska; J Cap; P Vlcek; J Duskova; D Kodetova; V Holub; Z Novak; B Bendlova
Journal:  Exp Clin Endocrinol Diabetes       Date:  2006-04       Impact factor: 2.949

5.  Pathogenicity of DNA variants and double mutations in multiple endocrine neoplasia type 2 and von Hippel-Lindau syndrome.

Authors:  Zoran Erlic; Michael M Hoffmann; Maren Sullivan; Gerlind Franke; Mariola Peczkowska; Igor Harsch; Matthias Schott; Helmut E Gabbert; Matti Valimäki; Simon F Preuss; Kornelia Hasse-Lazar; Dariusz Waligorski; Mercedes Robledo; Andrzej Januszewicz; Charis Eng; Hartmut P H Neumann
Journal:  J Clin Endocrinol Metab       Date:  2009-11-11       Impact factor: 5.958

6.  RET germline mutation in codon 791 in a family representing 3 generations from age 5 to age 70 years: should thyroidectomy be performed?

Authors:  Volker F H Brauer; Gerhard H Scholz; Susanne Neumann; Tobias Lohmann; Ralf Paschke; Christian A Koch
Journal:  Endocr Pract       Date:  2004 Jan-Feb       Impact factor: 3.443

7.  RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.

Authors:  Rossella Elisei; Cristina Romei; Barbara Cosci; Laura Agate; Valeria Bottici; Eleonora Molinaro; Mariangela Sculli; Paolo Miccoli; Fulvio Basolo; Lucia Grasso; Furio Pacini; Aldo Pinchera
Journal:  J Clin Endocrinol Metab       Date:  2007-09-25       Impact factor: 5.958

8.  RET mutation Tyr791Phe: the genetic cause of different diseases derived from neural crest.

Authors:  Eliska Vaclavikova; Sarka Dvorakova; Vlasta Sykorova; Radovan Bilek; Katerina Dvorakova; Petr Vlcek; Richard Skaba; Tomas Zelinka; Bela Bendlova
Journal:  Endocrine       Date:  2009-10-14       Impact factor: 3.633

9.  Seven-year follow-up of a juvenile female with papillary thyroid carcinoma with poor outcome, BRAF mutation and loss of expression of iodine-metabolizing genes.

Authors:  Gisele Oler; Claudia D Nakabashi; Rosa Paula M Biscolla; Janete M Cerutti
Journal:  Arq Bras Endocrinol Metabol       Date:  2008-11

10.  A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterization.

Authors:  Maria D Castellone; Antonella Verrienti; Deva Magendra Rao; Marialuisa Sponziello; Dora Fabbro; Magesh Muthu; Cosimo Durante; Marianna Maranghi; Giuseppe Damante; Stefano Pizzolitto; Giuseppe Costante; Diego Russo; Massimo Santoro; Sebastiano Filetti
Journal:  Clin Endocrinol (Oxf)       Date:  2010-10       Impact factor: 3.478

View more
  6 in total

Review 1.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

Review 2.  RET revisited: expanding the oncogenic portfolio.

Authors:  Lois M Mulligan
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

3.  Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility.

Authors:  Rodrigo A Toledo; Roxanne Hatakana; Delmar M Lourenço; Susan C Lindsey; Cleber P Camacho; Marcio Almeida; José V Lima; Tomoko Sekiya; Elena Garralda; Michel S Naslavsky; Guilherme L Yamamoto; Monize Lazar; Osorio Meirelles; Tiago J P Sobreira; Maria Lucia Lebrao; Yeda A O Duarte; John Blangero; Mayana Zatz; Janete M Cerutti; Rui M B Maciel; Sergio P A Toledo
Journal:  Endocr Relat Cancer       Date:  2014-11-25       Impact factor: 5.678

4.  Retroposed copies of RET gene: a somatically acquired event in medullary thyroid carcinoma.

Authors:  Larissa V Bim; Fábio C P Navarro; Flávia O F Valente; José V Lima-Junior; Rosana Delcelo; Magnus R Dias-da-Silva; Rui M B Maciel; Pedro A F Galante; Janete M Cerutti
Journal:  BMC Med Genomics       Date:  2019-07-09       Impact factor: 3.063

Review 5.  Multiple Endocrine Neoplasia Syndromes from Genetic and Epigenetic Perspectives.

Authors:  Fatemeh Khatami; Seyed Mohammad Tavangar
Journal:  Biomark Insights       Date:  2018-07-02

6.  The synergy of germline C634Y and V292M RET mutations in a northern Chinese family with multiple endocrine neoplasia type 2A.

Authors:  Zheng Yang; Xinmeng Qi; Neil Gross; Xiujuan Kou; Yunlong Bai; Yaru Feng; Bochun Wang; Mark E Zafereo; Guojun Li; Chuanzheng Sun; Huihui Li; Xiaohong Chen; Zhigang Huang
Journal:  J Cell Mol Med       Date:  2020-09-29       Impact factor: 5.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.